Q: Hi,
Please explain why RIGL (US) is down today about 22% after it went up yesterday 100% (mid-day).
My exceptions for the stock were to go up & up after RIGL announce it's trial being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of COVID-19 pneumonia
Thanks,
Morris